Bluehole New Consumption Publishes a Feature Story on Recent Vaping Regulation Updates

Rhea-AI Summary

China’s vaping industry is seeing regulatory advancements, as health regulators in the UK, US, and Malaysia are increasingly accepting e-cigarettes. On October 29, 2021, the UK announced plans for NHS prescription of e-cigarettes, while Malaysia imposed excise duties on nicotine products to promote compliance with safety standards. The US FDA granted marketing orders for Vuse Solo, marking a significant step for authorized e-cigarettes. This regulatory trend suggests a more standardized and competitive vaping market, benefiting leading companies like BAT and SMOORE.

Positive

• Increased regulatory acceptance of e-cigarettes by health authorities in the UK, US, and Malaysia.
• UK's NHS may prescribe e-cigarettes, marking a potential shift in tobacco cessation strategies.
• Malaysia's new excise duty may legitimize and standardize the vaping market.
• FDA's marketing orders for Vuse Solo indicate robust product approval processes.
• SMOORE's involvement with Vuse highlights its strong market position and compliance capabilities.

Negative

• FDA has denied marketing applications for 200,000 vaping products, indicating stringent market competition.

Accepted by more health regulators, the vaping industry will witness a more concentrated and standardized market

SHENZHEN, China--(BUSINESS WIRE)-- China’s leading vaping media, Bluehole New Consumption, today published a feature story on recent vaping regulation updates in the UK, the US and Malaysia. As vaping accepted by more and more health regulators, the industry will witness a more concentrated and standardized market.

Here below is the full article in English:

On October 29, 2021, the U.K government agency, Medicines and Healthcare Products Regulatory Agency (MHRA) announced that NHS could soon prescribe e-cigarettes to help tobacco smokers quit, inviting e-cigarette manufacturers to submit products to undergo the same approval process as prescribed medicines. It could make England the first country to prescribe medicinally licensed e-cigarettes. Under such a circumstance, “A medically licensed e-cigarette would have to pass even more rigorous safety checks than those required for them to be sold commercially,” according to BBC.

On the same day, the Malaysian government announced to impose excise duty on nicotine vapor products. The managing director of British America Tobacco (BAT) Malaysia, Nedal Salem, said this indicates the Malaysian government is looking to legalize nicotine vapor products: “Regulation will not only allow vape users access to reduced-risk alternatives to smoking, but also ensure the products used are compliant to quality and safety standards.”

Meanwhile, in October, the U.S Food and Drug Administration (FDA) has granted marketing orders for Vuse Solo and accompanying tobacco flavored e-liquid pods, making it the first set of e-cigarette authorized for sale by the FDA.

From the UK to Malaysia and the U.S, E-cigarette is accepted by more and more health regulators around the world as an effective harm-reduction tool to improve public health.

As BAT Malaysia states, regulation could positively accelerate healthy development of the vaping industry for setting higher quality requirements and safety standards for products. Moreover, regulation measures, such as the marketing authorization and prescription evaluation, could be deemed the regulators’ acknowledgement of the products’ public health benefits.

Besides, Mitch Zeller, director of the FDA Center for Tobacco Products, said that “many of the tobacco product reviews are in final stages,” at a virtual conference hosted by the Food and Drug Law Institute on October 27. However, the agency so far has only authorized three products for their substantial evidence of harm reduction while issuing marketing denial orders for 200 thousand products.

Vuse is currently in a lead position to pass the Premarket Tobacco Product Applications (PMTA) process. It showcases that the FDA (and perhaps other regulators) is more likely to trust and approve products made by market leaders for assured public health benefits and reliability proved by sufficient scientific data.

The FDA’s rigorous requirements for products are also applied to manufacturers. SMOORE, the world’s largest vaping manufacturer, is the strategic supplier of VUSE. It features PMTA-related non-clinical evaluation capabilities, including physical testing, chemical testing and health risk assessment. Moreover, SMOORE’s CNAS tests have also expanded to 134.

As the regulatory framework outlines a higher entry barrier for the industry, the global vaping industry will witness a more standardized and concentrated market where industry leaders, such as BAT and SMOORE, will further strengthen their leading positions. Meanwhile, the whole industry and the supply chain will benefit from such a well-regulated and standardized market in turn.

To read the original article, please visit: https://www.bluehole.com.cn/news/detail/47350

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006380/en/

Bluehole New Consumption Contact Info:

(+86)18612693874

CHEN ZHONG



SMOOR

Frankie Chen

(+86)13530848319

frankie.chen@smoorecig.com

Source: Bluehole New Consumption

FAQ

What recent advancements have impacted the vaping industry as of October 2021?

Recent policy changes in the UK, US, and Malaysia have positively influenced the vaping industry, increasing regulatory acceptance of e-cigarettes.

How may the UK NHS prescription plan for e-cigarettes alter the vaping market?

The NHS prescription plan could significantly increase the demand for medically licensed e-cigarettes, establishing a new revenue stream for manufacturers.

What does the FDA's approval of Vuse Solo imply for the vaping sector?

FDA's approval of Vuse Solo signals a more rigorous product approval process, pushing for higher industry standards and compliance.

How does Malaysia's excise duty on nicotine vapor products affect the market?

Malaysia's excise duty indicates an intention to regulate and standardize the vaping market, potentially improving product quality and safety.

What is the current status of FDA approvals for vaping products?

As of October 2021, the FDA has granted marketing orders for only a few vaping products, while denying a significant number, emphasizing stringent regulatory scrutiny.